A Systematic Review of Study Design and Placebo Controls in Psychedelic Research.
Alexander Wen, Nikhita Singhal, Brett D. M. Jones, Richard J. Zeifman, Shobha Mehta, Mohammad A. Shenasa, Daniel M. Blumberger, Zafiris J Daskalakis, Cory R. Weissman
Psychedelic Medicine March 12, 2024 DOI: 10.1089/psymed.2023.0028 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review with exploratory analysis Randomized Double-blind Peer reviewed |
|---|---|
| Sample size | 50 |
| Population | Randomized controlled trials involving classic psychedelics |
| Keywords | Psychedelic medicine Clinical research methodology Placebo controls Mental health treatments Research standards |
| Citations | 36 |
| Key findings | Blinding was unsuccessful in the studies that assessed it, and most trials did not report on blinding integrity. |
Abstract
Introduction: Effective blinding is especially challenging in randomized controlled trials (RCTs) involving psychedelics due to the inherent alterations in consciousness that these compounds induce. In this systematic review and exploratory analysis, we aim at synthesizing the methodologies used in RCTs involving classic psychedelics and identify procedures that can help minimize unblinding and bias.
Methods: We completed a literature search that included prospective RCTs published between 1963 and January 2023, in which participants were randomized to receive either a classic psychedelic or placebo.
Results: A total of 1402 papers were included in the initial search. After eligibility criteria were applied, 50 papers from 48 clinical trials were included. Most studies were double blinded ( n = 34), used a within-subjects design ( n = 32 studies), and included inert placebos ( n = 35). The majority of studies did not report on the integrity of blinding procedures ( n = 34 studies); however, in studies that did, blinding was unsuccessful.
Conclusion: To improve blinding and lower expectancy effects, we suggest incorporating active placebos and utilizing dose response or active comparator study designs.
Citations in the library
Cited by 33
- Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Scientific Reports April 17, 2024
- Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Molecular Psychiatry March 1, 2025
- From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS). Scientific Reports January 29, 2025
- Addressing blinding in classic psychedelic studies with innovative active placebos. The International Journal of Neuropsychopharmacology April 1, 2025
- Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression JAMA Network Open July 30, 2025
and 28 more in the library
Cites 55
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
and 50 more in the library